Compare XBIT & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | LNSR |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 69.1M |
| IPO Year | 2015 | 2005 |
| Metric | XBIT | LNSR |
|---|---|---|
| Price | $2.36 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 29.4K | ★ 113.9K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $58,435,000.00 |
| Revenue This Year | N/A | $10.06 |
| Revenue Next Year | N/A | $41.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.24 |
| 52 Week Low | $2.09 | $5.06 |
| 52 Week High | $3.61 | $13.43 |
| Indicator | XBIT | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 55.40 |
| Support Level | $2.26 | $5.33 |
| Resistance Level | $2.49 | $6.34 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 29.59 | 65.17 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.